{"prompt": "['LINEBERGER COMPREHENSIVE CANCER CENTER', 'CLINICAL ONCOLOGY RESEARCH PROGRAM', 'April 2017', 'UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL', 'PROTOCOL AMENDMENT #_8_', 'LCCC 1726: Randomized Placebo Controlled Trial of High Dose Intravenous', 'Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell', 'Transplantation', 'NCT03263442', 'Date Reviewed: 12/30/2020', 'Last Modified: 3/26/2020', 'AMENDMENT INCORPORATES (check all that apply):', 'X Editorial, administrative changes', 'Scientific changes (IRB approval)', 'Therapy changes (IRB approval)', 'Eligibility Changes (IRB approval)', 'AMENDMENT RATIONALE AND SUMMARY:', 'Editorial, administrative changes', '(1) The version date was updated throughout the protocol', '(2) In Sections 5.8 and 7.5 we have broadened allowable methods of follow-up', 'assessment to include email and online, in addition to in-person assessment, mail,', 'video conferencing, and over the phone. This enhances our ability to complete', 'study assessments and questionnaires whenever possible in cases that in-person', 'assessments (preferred method) are restricted or prohibited.', '(3) In Section 7.5 we have modified the follow-up assessment schedule to allow for', 'the three-month follow-up to be completed within four weeks of the specified', 'time point and the six-month follow-up to be completed within 2 months of the', 'specified time point. While we will make every attempt to schedule assessments', 'on their ideal dates, this will allow us more flexibility in scheduling in light of', 'COVID-19 policy.', 'Per the PRC Coordinator, this amendment is exempt from PRC review.', 'THE ATTACHED VERSION LAST MODIFIED 3/16/20 INCORPORATES THE', 'ABOVE REVISIONS']['LINEBERGER COMPREHENSIVE CANCER CENTER', 'CLINICAL ONCOLOGY RESEARCH PROGRAM', 'April 2017', 'UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL', 'ATTACH TO THE FRONT OF EVERY COPY OF PROTOCOL', 'PROTOCOL AMENDMENT #_7', 'LCCC 1726: Randomized Placebo Controlled Trial of High Dose Intravenous', 'Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell', 'Transplantation', 'AMENDMENT INCORPORATES (check all that apply):', 'X Editorial, administrative changes', 'Scientific changes (IRB approval)', 'Therapy changes (IRB approval)', 'Eligibility Changes (IRB approval)', 'AMENDMENT RATIONALE AND SUMMARY:', 'Editorial, administrative changes', '(1) The version date was updated throughout the protocol', '(2) We have removed Thomas Shea, MD as a co-investigator given his retirement', 'from UNC.', 'Per the PRC Coordinator, this amendment is exempt from PRC review.', 'THE ATTACHED VERSION DATED 1/14/20 INCORPORATES THE ABOVE', 'REVISIONS']['LINEBERGER COMPREHENSIVE CANCER CENTER', 'CLINICAL ONCOLOGY RESEARCH PROGRAM', 'April 2017', 'UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL', 'ATTACH TO THE FRONT OF EVERY COPY OF PROTOCOL', 'PROTOCOL AMENDMENT #__6_', 'LCCC 1726: Randomized Placebo Controlled Trial of High Dose Intravenous', 'Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell', 'Transplantation', 'AMENDMENT INCORPORATES (check all that apply):', 'X Editorial, administrative changes', 'Scientific changes (IRB approval)', 'Therapy changes (IRB approval)', 'Eligibility Changes (IRB approval)', 'AMENDMENT RATIONALE AND SUMMARY:', 'Editorial, administrative changes', '(1) The version date was updated throughout the protocol', '(2) In Sections 1.1, 4.1, 5.1, 7.2, and 9.1 we have modified language to expand', 'recruitment to the outpatient setting prior to planned allogeneic bone marrow', 'transplant, in addition to after patients are admitted. This allows us to have', 'additional time to secure formal insurance authorization prior to randomizing', 'participants to our study drug.', 'Per the PRC Coordinator, this amendment is exempt from PRC review.', 'THE ATTACHED VERSION DATED 8/13/19 INCORPORATES THE ABOVE', 'REVISIONS']\n\n###\n\n", "completion": "END"}